Details of the Drug

General Information of Drug (ID: DM8JQZC)

Drug Name
BNZ-1
Indication
Disease Entry ICD 11 Status REF
Cutaneous T-cell lymphoma 2B01 Phase 2 [1]
T-cell leukaemia 2A90 Phase 2 [2]
Large granular lymphocytic leukemia 2A90.1 Phase 1/2 [3]
Drug Type
Peptide
Cross-matching ID
TTD ID
DE09IO
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-15 (IL15) TTJFA35 IL15_HUMAN Inhibitor [4]
Interleukin-2 (IL2) TTF89GD IL2_HUMAN Inhibitor [4]
Interleukin-9 (IL9) TT0JTFD IL9_HUMAN Inhibitor [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Cutaneous T-cell lymphoma
ICD Disease Classification 2B01
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-2 (IL2) DTT IL2 7.64E-01 1.04E-02 0.07
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT03239392) A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL. U.S. National Institutes of Health.
4 Clinical pipeline report, company report or official report of Bioniz Therapeutics.